José Antonio Lorente Acosta, appointed director of the Innovation and Research Strategy in Health Counseling.

This roadmap, scheduled for the period 2014-2018, aims to improve care to citizens through knowledge generation.

Professor of Legal Medicine of the University of Granada José Antonio Lorente Acosta has been appointed director of the Strategy for Innovation and Research, I & I Health, 2014-2018 ofDepartment of Equality, Health and Social Policy. The main objective of this roadmap is to improve the health and social care to citizens through knowledge generation and product development, services and processes.

Born in Seron (Almería) in 1961, married with two daughters, Lorente is director of the Pfizer-University of Granada-Andalusian Center for Genomics and Oncology (GENYO) and Genetic Identification Laboratory of the University of Granada. Also, is vice president of the College of Physicians and Professor of Criminology Granada Andalusian Institute of Criminology.

His main clinical research GENYO focus on processes and tumor metastasis microenvironment, especially in the detection and study of circulating tumor cells (CTC), which maintains multiple collaborations with clinical groups of Andalusia and the rest of Spain, hospitals as well as Europe and the U.S..

José Antonio Lorente is the author of 144 national and international scientific publications, and over 195 papers. There have been scientific director and promoter of the Program 'FÉNIX’ Genetic Identification of Missing Persons, scientific director of the Program Agreement Genetic Identification of the Disappeared in Chile, Propeller Andaluz Maternal and Child ID Program in Genetics and manage humanitarian program DNA-Prokids.

The Strategy R i Health

The Andalusian will allocate this year 66,6 million euros for health research in the autonomous community. This was reflected in the Strategy of R i in Health 2014-2018, giving continuity to that developed during the period 2006-2013.

Through this initiative the effort of the Regional Administration in this area will continue and it will consolidate most network attached to the National Health System of Spain, over 65.000 facilities m, 190 Researchers career, five centers in biomedicine, four institutes of health research, un biobanco, ten public laboratories where advanced therapy medicinal products are manufactured, 15 ethics committees involving 300 experts and 117 records of intellectual property only in 2013.

One of the key elements of the strategy will be to maintain the current rate of active funding through attracting external resources and participation in research projects sponsored by European and national bodies. Another novelty of the strategy is the creation of a portfolio of services that will function as a tool for access to all research resources available in the autonomous community.

Overall, The document outlines three common axes to European public policy: momentum to a model of excellent science, priority to improving the health and quality of life of the population and support to business leadership in research and innovation orientation.